Pomalidomide, sold under the brand names Pomalyst and Imnovid,[7][8] is an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma.

[7] Pomalidomide was approved for medical use in the United States in February 2013,[10] and in the European Union in August 2013.

[8] In the United States, pomalidomide is indicated, in combination with dexamethasone, for people with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy;[12] and is indicated for people with AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy (HAART) or in people with Kaposi sarcoma who are HIV-negative.

[16] Based upon this discovery, thalidomide was taken into clinical trials for cancer, leading to its ultimate FDA approval for multiple myeloma.

[17] Structure-activity studies revealed that amino substituted thalidomide had improved antitumor activity, which was due to its ability to directly inhibit both the tumor cell and vascular compartments of myeloma cancers.